BioCryst Pharma (BCRX) PT Raised to $13 at JPMorgan

September 30, 2026 9:09 AM

JPMorgan analyst Jessica Fye raised the price target on BioCryst Pharma (NASDAQ: BCRX) to $13.00 (from $12.00) while maintaining a Neutral rating.

No results found